Actuate Therapeutics reports preclinical melanoma data showing up to 77% tumor growth inhibition
Actuate Therapeutics announced that oral dosing of its investigational drug elraglusib reduced tumor growth by as much as 77% in a mouse melanoma model, with twice‑daily dosing outperforming once‑daily dosing. The study, presented at the 38th EORTC‑NCI‑AACR Symposium, also showed enhanced CD8+ T‑cell and NK‑cell activity in tumors. Actuate intends to begin a Phase 1/2 study in Q1 2027, enrolling patients who have refractory metastatic melanoma.
Why it matters
The company says the preclinical exposure‑response data support moving the oral formulation into humans, so the upcoming Phase 1/2 trial could advance the pipeline and affect ACTU’s valuation. The announcement lifted ACTU’s share price, indicating market interest in the candidate.
Key facts
- 1Oral elraglusib achieved up to 77% tumor growth inhibition with twice‑daily dosing in a B16F10 melanoma mouse model. investing.com
- 2Once‑daily oral dosing produced 50% tumor growth inhibition in the same model. investing.com
- 3The preclinical results were presented at the 38th EORTC‑NCI‑AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026). investing.com
- 4Actuate plans to start a Phase 1/2 clinical trial in the first quarter of 2027, enrolling patients with refractory metastatic melanoma. investing.com
- 5Shares rose 13.58% to $0.28 following the announcement. rttnews.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.